Neoadjuvant Imatinib for an Uncommon Breast Malignancy Neoadjuvant Imatinib for an Uncommon Breast Malignancy
This case highlights the differentiation of dermatofibrosarcoma protuberans from metaplastic breast carcinoma and other spindle cell lesions, as well as the use of imatinib as neoadjuvant treatment.Journal of Medical Case Reports (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - February 18, 2020 Category: Surgery Tags: Family Medicine/Primary Care Journal Article Source Type: news

Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet...
Source: Johnson and Johnson - February 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Less chemotherapy may have more benefit in rectal cancer
(University of Colorado Anschutz Medical Campus) GI Cancers Symposium: Colorado study of 48 patients with locally advanced rectal cancer receiving neoadjuvant chemotherapy, found that patients receiving lower-than-recommended doses in fact saw their tumors shrink more than patients receiving the full dose. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 30, 2020 Category: Cancer & Oncology Source Type: news

Neoadjuvant checkpoint blockade for cancer immunotherapy
Cancer immunotherapies that target the programmed cell death 1 (PD-1):programmed death-ligand 1 (PD-L1) immune checkpoint pathway have ushered in the modern oncology era. Drugs that block PD-1 or PD-L1 facilitate endogenous antitumor immunity and, because of their broad activity spectrum, have been regarded as a common denominator for cancer therapy. Nevertheless, many advanced tumors demonstrate de novo or acquired treatment resistance, and ongoing research efforts are focused on improving patient outcomes. Using anti–PD-1 or anti–PD-L1 treatment against earlier stages of cancer is hypothesized to be one such ...
Source: ScienceNOW - January 30, 2020 Category: Science Authors: Topalian, S. L., Taube, J. M., Pardoll, D. M. Tags: Immunology, Medicine, Diseases, Online Only review Source Type: news

Breast Conservation After Neoadjuvant Chemotherapy Less Common in US Than Elsewhere Breast Conservation After Neoadjuvant Chemotherapy Less Common in US Than Elsewhere
Neoadjuvant systemic therapy can facilitate breast conservation in certain women with stage II and III operable breast cancer. But compared to other countries, significantly fewer women in the United States make such a choice.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 15, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Circulating Tumor DNA May Identify Disease Progression in Patients with Rectal Cancer
Researchers assessed whether ctDNA could accurately differentiate metastases during the neoadjuvant period after surgery to guide therapy adaptation. (Source: CancerNetwork)
Source: CancerNetwork - January 15, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

T-DM1, Lapatinib, Nab-paclitaxel in HER2+ Breast Cancer T-DM1, Lapatinib, Nab-paclitaxel in HER2+ Breast Cancer
Should dual HER2 blockade plus nab-paclitaxel be considered for neoadjuvant treatment of HER2+ breast cancer?Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 7, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Zoledronic Acid and Neoadjuvant Chemo in HER2- Breast Cancer Zoledronic Acid and Neoadjuvant Chemo in HER2- Breast Cancer
While adjuvant bisphosphonates are associated with longer survival in postmenopausal women with breast cancer, the same cannot be said for neoadjuvant bisphosphonates.Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 24, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

European Commission approves Roche ’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
             Basel, 19 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Kadcyla ® (trastuzumab emtansine) for the adjuvant (after surgery) treatment of adult patients with HER2-positive early breast cancer (eBC) who have residual invasive disease in the breast and/or lymph nodes after neoadjuvant (before surgery) taxane-based and HER2-targeted therapy.“Optimal treatment is vital for every patient with early-stage breast cancer, a setting where cures are possible,” said Levi Garraway, ...
Source: Roche Media News - December 19, 2019 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
Basel, 19 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Kadcyla ® (trastuzumab emtansine) for the adjuvant (after surgery) treatment of adult patients with HER2-positive early breast cancer (eBC) who have residual invasive disease in the breast and/or lymph nodes after neoadjuvant (before surgery) taxane-based and HER2-targeted therapy.“Optimal treatment is vital for every patient with early-stage breast cancer, a setting where cures are possible,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product De...
Source: Roche Investor Update - December 19, 2019 Category: Pharmaceuticals Source Type: news

Omit Surgery in Early-Stage Breast Cancer? Not Yet Omit Surgery in Early-Stage Breast Cancer? Not Yet
It's an enticing idea in an age of breast cancer treatment de-escalation: omit surgery if a patient achieves what looks like a complete response to neoadjuvant chemotherapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 17, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Julia White, MD, Discusses Tailored Local Therapy Treatment in Breast Cancer
The professor of radiation oncology discussed these tailored treatments for when patients receive neoadjuvant chemotherapy, and they get a complete pathologic response. (Source: CancerNetwork)
Source: CancerNetwork - December 17, 2019 Category: Cancer & Oncology Authors: Julia White, MD Source Type: news

Outcomes in TN Breast Cancer Predicted by Blood Biomarkers Outcomes in TN Breast Cancer Predicted by Blood Biomarkers
Biomarkers of residual disease at surgery identify which triple-negative breast cancer patients already treated with neoadjuvant therapy will do well and which will do poorly over the next 2 years.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 16, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Promising New Neoadjuvant Strategy in Luminal B Breast Cancer Promising New Neoadjuvant Strategy in Luminal B Breast Cancer
The combination of ribociclib and letrozole proved to a viable alternative to standard multidrug neoadjuvant chemotherapy for women with high-risk luminal B breast cancer in an exploratory phase 2 trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 16, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Residual cancer burden after neoadjuvant therapy can accurately predict breast cancer survival
(University of Texas M. D. Anderson Cancer Center) Researchers from The University of Texas MD Anderson Cancer Center today reported results from a pooled analysis of more than 5,100 breast cancer patients that found residual cancer burden (RCB) continuous index and classification were independently and strongly prognostic for all breast cancer phenotypes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 13, 2019 Category: Cancer & Oncology Source Type: news

Research affirms imaging technique's ability to characterize healthy and non-healthy tissue
(SPIE--International Society for Optics and Photonics) In an article published in the peer-reviewed SPIE publication Journal of Biomedical Optics (JBO), 'Influence of neoadjuvant chemotherapy on diffuse reflectance spectra of tissue in breast surgery specimens,' research observed across 92 ex vivo breast specimens suggests that there is little to no impact on the optical signatures of breast tissue after neoadjuvant chemotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 27, 2019 Category: Cancer & Oncology Source Type: news

Neoadjuvant Chemotherapy for Primary Sarcoma of the Breast Neoadjuvant Chemotherapy for Primary Sarcoma of the Breast
This case suggests that breast sarcomas could be treated in the same way as other soft tissue sarcomas in terms of adjuvant chemotherapy.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 20, 2019 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

CHMP recommends EU approval of Roche ’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
Roche today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Kadcyla® (trastuzumab emtansine) for the adjuvant (after surgery) treatment of adult patients with HER2-positive early breast cancer (eBC) who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant (before surgery) taxane-based and HER2-targeted therapy. (Source: Roche Media News)
Source: Roche Media News - November 15, 2019 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
Roche today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Kadcyla® (trastuzumab emtansine) for the adjuvant (after surgery) treatment of adult patients with HER2-positive early breast cancer (eBC) who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant (before surgery) taxane-based and HER2-targeted therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - November 15, 2019 Category: Pharmaceuticals Source Type: news

Metastatic Breast Cancer Highlights From ESMO 2019 Metastatic Breast Cancer Highlights From ESMO 2019
Metastatic breast cancer highlights from ESMO 2019 confirm that CDK4/6 inhibition gives survival benefit in HR+/HER2- breast cancer and that immunotherapy is active in the neoadjuvant setting in TNBC.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 21, 2019 Category: Consumer Health News Tags: None ReCAP Source Type: news

What Factors Can Predict Response to HER2-Directed Neoadjuvant Therapy?
Several clinicopathologic features of HER2-positive breast cancer patients were found to be associated with response to neoadjuvant therapy in a new study. (Source: CancerNetwork)
Source: CancerNetwork - October 16, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Neoadjuvant T-DM1 and Pertuzumab in HER2+ Breast Cancer Neoadjuvant T-DM1 and Pertuzumab in HER2+ Breast Cancer
Is neoadjuvant T-DM1 plus pertuzumab associated with better event-free survival than conventional neoadjuvant therapy for HER2+ breast cancer?Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 15, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Laparoscopic Procedures Provide Better Outcomes in Gastric Cancer
Laparoscopy-assisted distal gastrectomy offered better short-term, post-surgical outcomes for patients with locally advanced gastric cancer who were undergoing neoadjuvant chemotherapy.   (Source: CancerNetwork)
Source: CancerNetwork - October 8, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Laparoscopic Gastrectomy May Be Preferable After Gastric-Cancer Chemo Laparoscopic Gastrectomy May Be Preferable After Gastric-Cancer Chemo
In patients with locally advanced gastric cancer, laparoscopy-assisted distal gastrectomy (LADG) after neoadjuvant chemotherapy appears to offer more short-term benefits than does open gastrectomy, according to Chinese researchers.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - October 8, 2019 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news

Pembrolizumab Plus Chemo Boosts Response in Triple-Negative Breast Cancer
Adding the immunotherapy pembrolizumab to neoadjuvant chemotherapy improved the pathological complete response rate in patients with early triple-negative breast cancer, according to findings of a study presented at ESMO. (Source: CancerNetwork)
Source: CancerNetwork - September 30, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

ASTRO Issues Guideline for Radiation Tx in Pancreatic Cancer
Evidence reviewed for radiation therapy in adjuvant, neoadjuvant, definitive, and palliative settings (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 19, 2019 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Pharmacy, Radiology, Journal, Source Type: news

FDA-BCAN Workshop: Endpoints for the Development of Neoadjuvant Systemic Therapy Regimens for Muscle-Invasive Bladder Cancer - 08/08/2019 - 08/08/2019
This workshop focuses on endpoints for the development of systemic neoadjuvant therapies for the treatment of muscle-invasive bladder cancer. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - September 17, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA-MRA Approaches to Neoadjuvant Treatment in Melanoma: A Public Workshop - 11/06/2019 - 11/06/2019
Public Workshop (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - September 6, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Can PI3K Inhibitors Reduce Endocrine Therapy Resistance in Early Breast Cancer?
The new phase II LORELEI trial tested whether the PI3K inhibitor taselisib could improve response rates when added to letrozole in the neoadjuvant setting. (Source: CancerNetwork)
Source: CancerNetwork - August 28, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Standardization Arrives for Neoadjuvant Trials in Melanoma
The new recommendations will help standardize  neoadjuvant clinical trial methodology and develop a path for regulatory review and approval of neoadjuvant therapies in melanoma. (Source: CancerNetwork)
Source: CancerNetwork - August 6, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

Neoadjuvant Radiotherapy Beneficial in Resectable Liver Cancer With Portal Vein Tumor Thrombus Neoadjuvant Radiotherapy Beneficial in Resectable Liver Cancer With Portal Vein Tumor Thrombus
Neoadjuvant three-dimensional conformal radiotherapy (RT) followed by hepatectomy boosts outcomes over those with hepatectomy alone in patients with resectable hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT), researchers from China report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 3, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

' A Really Big Year' for Lung Cancer Treatment'A Really Big Year' for Lung Cancer Treatment
Dr Mark Kris reviews promising new research in neoadjuvant and adjuvant therapies for lung cancer, presented at ASCO 2019.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 30, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Lymphedema After Axillary Node Dissection Linked With Obesity, Longer Neoadjuvant Chemo Lymphedema After Axillary Node Dissection Linked With Obesity, Longer Neoadjuvant Chemo
Increasing body mass index and longer neoadjuvant chemotherapy (NAC) are associated with a higher risk of lymphedema in women who undergo axillary lymph node dissection, researchers say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 26, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Skipping Surgery in Rectal Cancer: Better or Worse? Skipping Surgery in Rectal Cancer: Better or Worse?
' Unreliable'assessment of complete clinical response after neoadjuvant chemoradiotherapy for rectal cancer means a watch-and-wait strategy should be followed with caution, suggest results of an expert debate.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 17, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

' Pick the Winner' Trial in Rectal Cancer: Chemoradiation First'Pick the Winner' Trial in Rectal Cancer: Chemoradiation First
A'pick the winner'trial found that chemoradiation followed by chemo wins in total neoadjuvant therapy for locally advanced rectal cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 5, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Early Breast Cancer Highlights From ASCO 2019 Early Breast Cancer Highlights From ASCO 2019
Dr Harold Burstein highlights ASCO oral presentations on early breast cancer, featuring neoadjuvant therapy in HER2-positive disease and updated data from the TAILORx study in HR-positive disease.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 21, 2019 Category: Consumer Health News Tags: None ReCAP Source Type: news

Can T-DM1 Match Chemotherapy Plus Dual Blockade in HER2+ Breast Cancer?
A phase II trial tested docetaxel, trastuzumab, and pertuzumab vs T-DM1 for the neoadjuvant treatment of HER2+ breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 14, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Nintedanib Worsens Outcomes Along With Chemo in Advanced Ovarian Cancer
A phase II trial showed that the addition of nintedanib to neoadjuvant chemotherapy did not benefit patients with advanced epithelial ovarian cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 11, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Novel Neoadjuvant Approach May Boost Surgical Success in Pancreatic Cancer Novel Neoadjuvant Approach May Boost Surgical Success in Pancreatic Cancer
In the majority of studied patients with locally advanced pancreatic cancer, total neoadjuvant treatment with fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFIRINOX) along with losartan and chemoradiation allowed complete tumor removal, according to a single-arm phase 2 trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 10, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Breast Cancer at ASCO 2019: IO, CDK4/6i, and New Approvals Breast Cancer at ASCO 2019: IO, CDK4/6i, and New Approvals
Drs Miller and Burstein discuss advances presented at ASCO 2019 in immunotherapy, CDK4/6 inhibitors, and neoadjuvant TDM-1 therapies for breast cancer.Medscape Oncology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - June 7, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology Commentary Source Type: news

Outcomes With Experimental Neoadjuvant T-VEC in Resectable Stage IIIB-IVM1a Melanoma
Data from the largest  randomized neoadjuvant trial in resectable stage IIIB–IVM1a melanoma to date were presented at ASCO 2019. (Source: CancerNetwork)
Source: CancerNetwork - June 7, 2019 Category: Cancer & Oncology Authors: Lauren M. Dembeck Source Type: news

Combination checkpoint blockade effective in pre-surgical setting for early-stage lung cancers
(University of Texas M. D. Anderson Cancer Center) Neoadjuvant, or pre-surgical, treatment with nivolumab plus ipilimumab resulted in an overall major pathologic response (MPR) rate of 33 percent of treated patients with early-stage, resectable non-small cell lung cancers, meaning these patients had less than or equal to 10 percent viable tumor remaining at surgery. With these results, the combination immunotherapy met the pre-specified trial efficacy endpoint of the phase II NEOSTAR trial conducted by researchers at The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 3, 2019 Category: International Medicine & Public Health Source Type: news

Neoadjuvant Immune Checkpoint Inhibitor Combo Promising for NSCLC
Researchers compared the percentage of  non-viable tumor and tissue resident memory tumor infiltrating lymphocytes for nivolumab plus ipilimumab vs nivolumab alone. (Source: CancerNetwork)
Source: CancerNetwork - June 2, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news

NRG trial suggests total neoadjuvant therapy for locally advanced rectal cancer is safe
(NRG Oncology) Results from the first experimental arm using veliparib as part of total neoadjuvant therapy (induction chemotherapy followed by chemoradiotherapy and surgery; TNT) in patients with locally advanced rectal adenocarcinoma on the NRG Oncology Phase II clinical trial NRG-GI002 were recently presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 1, 2019 Category: Cancer & Oncology Source Type: news

Stand up to cancer-funded research to be presented at ASCO May 31-June 4 in Chicago
(Stand Up To Cancer) SU2C supported researchers will present work on pediatric brain tumors, cfDNA for early cancer detection, dual blockade of CTLA-4 and PD-1 in mCRC, cancer interception of pancreatic and lung cancers, machine learning RECIST in RWE study of lung cancer, and molecular markers of response to neoadjuvant nivolumab in resectable NSCLC. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - May 30, 2019 Category: International Medicine & Public Health Source Type: news

Skipping Surgery for HER2+ Breast Cancer: Which Patients? Skipping Surgery for HER2+ Breast Cancer: Which Patients?
New findings have identified factors associated with pathological complete response (pCR) following neoadjuvant treatment, which will help identify patients who could skip surgery.Medscape Medical News (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - May 8, 2019 Category: Surgery Tags: Hematology-Oncology News Source Type: news

New Lesions ID ’ d on Breast MRI During Treatment Likely Benign
New suspicious lesions detected on breast MRI during neoadjuvant therapy are more likely benign (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 7, 2019 Category: Cancer & Oncology Tags: Gynecology, Oncology, Radiology, Conference News, Source Type: news

Packing a PUNCH in Prostate Cancer: Chemo & ADT & Surgery Packing a PUNCH in Prostate Cancer: Chemo & ADT & Surgery
Investigators of the Preoperative Use of Neoadjuvant Chemotherapy (PUNCH) trial say that this experimental approach should now be a standard in high-risk, localized disease. An expert rejects the idea.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 7, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New Lesions ID'd on Breast MRI During Treatment Likely Benign
TUESDAY, May 7, 2019 -- For patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer, magnetic resonance imaging (MRI) examinations with new suspicious findings are unlikely to represent a new site of malignancy, according to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 7, 2019 Category: Pharmaceuticals Source Type: news

Frequency and outcomes of new suspicious lesions on breast MRI in neoadjuvant therapy
(American Roentgen Ray Society) During neoadjuvant chemotherapy, new suspicious findings detected on breast magnetic resonance imaging (MRI) during neoadjuvant therapy are most likely benign, according to a study to be presented at the ARRS 2019 Annual Meeting, set for May 5-10 in Honolulu, Hawaii. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 7, 2019 Category: Cancer & Oncology Source Type: news